Ron

In July, Outside magazine ran a profile of a woman named Elizabeth Parrish. “Liz Parrish Wants to Live Forever,” the headline shouted. A few years earlier, in 2015, Parrish had become the first human guinea pig in an experiment intended to reverse aging through gene therapy. She, and the scientists who designed the therapy, were

Houston-based biopharmaceutical company Tvardi Therapeutics Inc., which was co-founded by former University of Texas M.D. Anderson Cancer Center president Dr. Ronald DePinho, named Imran Alibhai as its CEO, effective immediately. Alibhai most recently served as a senior vice president and managing director of Houston-based DNAtrix Inc., a clinical-stage biopharmaceutical company developing oncolytic viruses for cancer,

Host, Dr. Robin Smith, chats with Dr. Ron DePinho, professor of medicine and former president of the University of Texas MD Anderson Cancer Center in Houston and an internationally recognized physician for his basic and translational research in cancer, aging, and age-associated degenerative disorders. DePinho launched the Cancer Moonshot Program, played a critical role in

Ron DePinho, a current professor and past president of the University of Texas M.D. Anderson Cancer Center, founded a private cancer drug company that recently closed a $9 million funding round. Tvardi Therapeutics Inc. develops a cancer drug that acts as an inhibitor to STAT3 — a signaling molecule in our cells that, when left

As longtime supporters of the University of Texas MD Anderson Cancer Center, it gives us a sense of pride and accomplishment to see the great work of our very own Dr. Jim Allison recognized with the 2018 Nobel Prize in Medicine. This is the first such prize awarded to an MD Anderson scientist, and we